Rifampicin: Action against Tuberculosis and Mycobacteria
Rifampicin (trade names Eremfat, Rifa, Rimactan and generics) is a semisynthetic antibiotic from the rifamycin group. It was introduced in the 1960s and has since been a central component of tuberculosis therapy. In Germany, rifampicin is approved for the treatment of tuberculosis, leprosy, and selected other indications such as severe staphylococcal infections with implant involvement. The substance has high therapeutic potential, but at the same time a massive effect on hepatic drug metabolism characterizes its clinical use.
Rifampicin is one of the most potent clinically relevant inducers of CYP enzymes and P glycoprotein. Anyone prescribing rifampicin must systematically review all concomitant medication, because numerous active substances lose their effectiveness, such as warfarin, hormonal contraceptives, some antiretroviral substances, calcium antagonists, and many others. The typical red discoloration of urine, sweat, and tears is also clinically important because it can alarm patients without proper counseling.
Mechanism of Action
Rifampicin inhibits the DNA dependent RNA polymerase of bacteria. It binds to the beta subunit of the enzyme and blocks the initiation of RNA synthesis. The result is a collapse of bacterial protein synthesis and a bactericidal effect against both dividing and resting bacteria. This property makes rifampicin particularly valuable in tuberculosis therapy because Mycobacterium tuberculosis undergoes long phases of slow metabolic activity.
The spectrum of activity includes Mycobacterium tuberculosis, M. leprae, atypical mycobacteria (M. avium complex, M. kansasii), Staphylococcus aureus including MRSA, streptococci, Neisseria meningitidis, and some other pathogens. Because of rapid resistance development, rifampicin in tuberculosis is always used in combination with other active substances such as isoniazid, pyrazinamide, and ethambutol. In staphylococcal infections, it is often combined with flucloxacillin, vancomycin, or linezolid.
Pharmacokinetically, rifampicin is characterized by high oral bioavailability (approximately 90 percent), very good tissue distribution including cerebrospinal fluid and intracellular spaces, and predominantly hepatic elimination. The half life is initially approximately three to four hours but shortens through self induction of CYP enzymes after several weeks.
Fields of Application
- Tuberculosis, all localizations, always in combination therapy
- Latent tuberculosis infection as part of short term regimens, for example three or four months of rifampicin
- Leprosy, component of WHO multidrug therapy
- Atypical mycobacterioses (M. avium complex, M. kansasii), combined with other antimycobacterial active substances
- Severe staphylococcal infections with biofilm, for example in implant associated infections, endocarditis, prosthesis related spondylodiscitis, always in combination
- Post exposure prophylaxis for meningococcal disease, short term in the environment of index cases
- Brucellosis and selected other indications in specialized therapy
Rifampicin is not suitable as monotherapy because resistances develop rapidly. Use is also critical in acute hepatitis or cholestasis. In HIV positive patients, there are numerous interactions with antiretroviral substances, specialized consultation is essential.
Dosage and Administration
Tuberculosis adults: 10 mg per kg body weight once daily orally, usually 600 mg in patients weighing 50 kg or more. Maximum dose 600 mg per day. For high dose therapy regimens, research is being conducted on higher doses.
Tuberculosis pediatric: 15 mg per kg per day, maximum 600 mg.
Leprosy: 600 mg once monthly as part of multidrug therapy.
Staphylococcal implant infection: 600 mg one or two times daily in combination with another effective antibiotic.
Post exposure prophylaxis meningococcal: 600 mg twice daily for two days.
Administration: on an empty stomach, at least one hour before or two hours after a meal. Take with plenty of water. Maintain a two hour interval from antacids.
Renal insufficiency: generally no dose adjustment required because hepatic elimination is dominant. Hepatic insufficiency: in pre existing liver disease, close monitoring of liver function tests, dose adjustment individual.
Adverse Effects
Very common: Red discoloration of urine, sweat, tears, saliva. This discoloration is harmless but can be alarming to patients without proper counseling. Contact lenses can become permanently discolored.
Common: Nausea, abdominal pain, diarrhea, loss of appetite, elevation of liver transaminases.
Uncommon: Hepatitis up to liver insufficiency, rash, pruritus, fever, eosinophilia.
Rare but relevant: Thrombocytopenia, hemolytic anemia, acute renal insufficiency, Stevens Johnson syndrome, DRESS syndrome, so called flu like syndrome (fever, chills, muscle pain) with intermittent therapy.
Hepatotoxicity: in combination with isoniazid and pyrazinamide, cumulative risk, especially with alcohol abuse, hepatitis B or C, older patients. Regular liver function monitoring is mandatory.
Endocrine and metabolic: Hyperuricemia, in individual cases worsened diabetes management.
Drug Interactions
- Hormonal contraceptives: significantly reduced effectiveness, additional contraception (condom or copper intrauterine device) necessary.
- Anticoagulants (vitamin K antagonists, DOACs): reduced levels, INR monitoring and dose adjustment.
- Glucocorticoids: reduced effectiveness, higher doses often necessary.
- Antiretroviral substances: greatly reduced levels of protease inhibitors, some NNRTIs, and integrase inhibitors. Specialized HIV counseling required, rifabutin often an alternative.
- Calcium antagonists, statins, antiepileptic drugs, immunosuppressants: levels decrease, loss of effectiveness possible.
- Antidiabetic agents (sulfonylureas, repaglinide): effectiveness reduced, metabolic control important.
- Methadone and opioids: loss of effectiveness, withdrawal symptoms possible, adjust dose.
- Triazoles, voriconazole, itraconazole: greatly reduced antifungal levels, therapy failure threatens.
- Atorvastatin, simvastatin, lovastatin: reduced levels, consider switching to statins less dependent on CYP3A4.
- Levothyroxine: increased hormone requirement possible, TSH monitoring.
- Trazodone, some antidepressants: reduced effectiveness, monitor clinical course.
Special Information
Pregnancy: Rifampicin is considered necessary in pregnancy for tuberculosis because treatment success is vital. A theoretical bleeding risk in the newborn due to vitamin K antagonism is compensated by vitamin K supplementation in the newborn. Breast feeding: Transfer into breast milk in small amounts, breast feeding during therapy usually acceptable.
Children: established in pediatrics, dose weight adapted.
Elderly patients: increased hepatotoxicity, close liver function monitoring.
Before therapy begins: History of liver disease, alcohol consumption, hepatitis B and C, previous tuberculosis treatments, medication history with particular attention to drug interactions, HIV status. Complete blood count, liver function tests, bilirubin, creatinine, uric acid, pregnancy test.
Monitoring: in the first weeks liver function tests every two to four weeks, later every two to three months. In case of signs of hepatotoxicity (nausea, fatigue, jaundice, dark urine), adjust therapy immediately. Eye examination in tuberculosis combination therapy because of ethambutol.
Patient counseling: Red discoloration of body fluids, drug interactions, contraceptive measures, regular administration. Therapy adherence is critical in tuberculosis because irregular administration promotes resistance development.
DOT (Directly Observed Therapy): if compliance is unreliable, therapy can be administered under supervision.
You May Also Be Interested In
- Clarithromycin, macrolide with similar CYP interactions
- Erythromycin, older macrolide with CYP3A4 inhibition
- Flucloxacillin, penicillin for staphylococcal infections
- Vancomycin, glycopeptide for MRSA and severe gram positive infections
- Itraconazole, triazole antifungal with significant interaction with rifampicin
Frequently Asked Questions
Why does urine and tear fluid discolor under rifampicin?
Rifampicin and its metabolites have an intense red orange color. They are excreted via urine, sweat, tears, and saliva. The discoloration is harmless but can cause permanent discoloration of contact lenses. Counseling at the start of therapy prevents confusion.
Why doesn't my birth control pill work anymore under rifampicin?
Rifampicin is a potent inducer of CYP3A4. Hormonal contraceptives are thereby broken down faster, their effectiveness drops below the safe threshold. During rifampicin use and for at least four weeks afterwards, an additional contraceptive method such as a condom or copper intrauterine device is required.
How long does tuberculosis therapy with rifampicin take?
Standard duration is six months, consisting of two months initial phase with four active substances (rifampicin, isoniazid, pyrazinamide, ethambutol) and four months consolidation phase with rifampicin and isoniazid. In resistant pathogens or special localizations, therapy is prolonged.
What to do if sudden nausea and fatigue occur under rifampicin?
Hepatotoxicity is a significant risk. Nausea, vomiting, fatigue, dark urine, and yellowing of the skin or eyes are warning signs. Immediate medical evaluation with liver function testing. Therapy interruption may be necessary, restart after normalization is undertaken cautiously and with close monitoring.
Sources
- Gelbe Liste, Rifampicin Active Ingredient Profile
- BfArM, Federal Institute for Drugs and Medical Devices
- AWMF, S2k Guideline Tuberculosis
- WHO, Guidelines for treatment of tuberculosis and leprosy
- Robert Koch Institute, Tuberculosis Surveillance
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or therapy recommendation. It does not replace the advice of a licensed physician or pharmacist. Tuberculosis and leprosy are complex diseases whose therapy should be conducted exclusively in specialized settings. All information is based on expert information published at the time of creation and recognized scientific sources, with the current package insert of the manufacturer always being authoritative. Sanoliste assumes no liability for completeness, currency, or accuracy of the information presented. In a medical emergency, call the emergency number 112.